Hepatic fibrosis and cirrhosis are a growing global health problem with increasing mortality rates. Early diagnosis and staging of hepatic fibrosis represent a major challenge. Currently liver biopsy is the gold standard for fibrosis assessment; however, biopsy requires an invasive procedure and is prone to sampling error and reader variability. In the current study we investigate using quantitative analysis of computer-extracted features of B-mode ultrasound as a non-invasive tool to characterize hepatic fibrosis. Twenty-two rats were administered diethylnitrosamine (DEN) orally for 12 weeks to induce hepatic fibrosis. Four control rats did not receive DEN. B-mode ultrasound scans sampling throughout the liver were acquired at baseline, 10, and 13 weeks. Computer extracted quantitative parameters representing brightness (echointensity, hepatorenal index) and variance (heterogeneity, anisotropy) of the liver were studied. DEN rats showed an increase in echointensity from 37.1 ± SD 7.8 to 53.5 ± 5.7 (10 w) to 57.5 ± 6.1 (13 w), while the control group remained unchanged at an average of 34.5 ± 4.5. The three other features studied increased similarly over time in the DEN group. Histologic analysis showed METAVIR fibrosis grades of F2-F4 in DEN rats and F0-F1 in controls. Increasing imaging parameters correlated with increasing METAVIR grades, and anisotropy showed the strongest correlation (ρ = 0.58). Sonographic parameters combined using multiparametric logistic regression were able to differentiate between clinically significant and insignificant fibrosis. Quantitative B-mode ultrasound imaging can be implemented in clinical settings as an accurate non-invasive tool for fibrosis assessment.
In the United States, chronic liver disease and its end state of cirrhosis represent the fifth leading cause of death for people aged 45 to 54 years and the 12th leading cause of death overall, independent of associated deaths from liver cancer and complications of liver disease1. In the last two decades, mortality in the United States due to cirrhosis increased by 65%, with a specific increase in deaths of younger people ages 25–342. The most common causes of cirrhosis are alcoholic liver disease, hepatitis C, and hepatitis B. Additionally, cirrhosis due to metabolic syndrome-induced non-alcoholic fatty liver disease is increasing. In all of these conditions, chronic inflammation of the liver leads to hepatic fibrosis and scarring, which progresses to cirrhosis. Given cirrhosis’ growing burden of disease, and its preventability through treatment and reversal of early stages of fibrosis, an easily-accessible assessment of fibrosis is imperative3,4,5.
The gold standard for assessing fibrosis is hepatic biopsy with subsequent analysis by pathologists. Biopsy is performed percutaneously or transjugularly, and the level of fibrosis is graded by pathologists using a semi-quantitative system such as the METAVIR system6. However, there are limitations to hepatic biopsy, including complications of the invasive procedure, sampling error, and intra- and interobserver variability6,7. These limitations highlight the need for alternative methods of assessing fibrosis that are noninvasive, minimize sampling error, and are objective. Proposed alternatives include radiologic tests and laboratory tests for hematological, biochemical, and direct markers of fibrosis8,9. Transient elastography, or FibroScan, has emerged as a promising sonographic technique to measure the elasticity of the liver, which becomes less elastic as fibrosis progresses8,9. While a meta-analysis found a mean area under the receiver operating characteristic curve (AUROC) of 0.94 for cirrhosis, the accuracy of differentiating clinically significant fibrosis at lower levels (F0/1 vs. F2/3/4) was weaker (AUROC = 0.84)10. Similarly, accuracy of ARFI in diagnosing fibrosis drops from AUC of 0.92 for cirrhosis to 0.87 for clinically significant fibrosis of F2 or greater11. Thus, improvement of tools assessing hepatic fibrosis can be especially helpful to monitor fibrosis early its course.
Toward this goal, the computerized analysis of liver features on B-mode ultrasound (US), which is widely available and used commonly in the clinic, could help to noninvasively characterize the progression of fibrosis. While US examinations have been used to detect fatty liver disease in humans12,13,14,15,16,17, less attention has been given to its potential for monitoring hepatic fibrosis. Studies focusing on hepatic fibrosis have largely assessed qualitative structural changes on ultrasound that are visible by eye18. However, computerized analysis of ultrasound images may provide measurements of liver fibrosis on a more continuous scale using unbiased quantitative imaging biomarkers. This correlation of quantitative radiographic measures with clinical states and outcomes is utilized in radiomics. Thus far, the use of radiomics in US has likely been limited by the variability of US acquisition and data extraction19. However, the advancement of standardization techniques such as the hepatorenal index to normalize tissue echointensity within a subject20,13 and the development of automated parameter maps to standardize analytical outputs support the utility of US radiomics19. Applying computerized analysis to the liver may allow for measurement of fibrosis from common, standard B-mode abdominal examinations using quantitative continuous measures.
In this study we image fibrosis as it develops over time, using a diethylnitrosamine (DEN)-induced rat model of liver injury that closely mimics human inflammatory liver disease. DEN produces primary metabolic activation and DNA alkylation, leading to hepatic necrosis, inflammation, fibrosis, and eventual carcinogenesis in a controlled setting not possible in human subjects21,22,23. We utilize quantitative analysis of computer extracted parameters from B-mode US images to widely sample and noninvasively characterize the progression of hepatic fibrosis.
The effect of diethylnitrosamine is demonstrated by changes in weight over time and confirmed by histopathologic analysis
The initial weight of all animals was between 350–400 g. The weights of the 22 rats in the DEN cohort (396 g ± SD 52 g) lagged below control animals’ weights (445 g ± 32) by the second week of the diet (p = 0.003 at day 17 of diet) and remained lower for the remainder of the experiment. The final weight of DEN-exposed group was 447 g ± 80; the final weight of controls was 633 g ± 43 (p = 0.0005). The DEN-exposed animals developed liver disease and multiple foci of hepatocellular carcinoma (HCC), seen on gross pathology and histologic analysis. These changes were not seen in the control cohort.
Ultrasound images of DEN-exposed livers reveal changes in quantitative measures of brightness and variance over time
When scanned at baseline before exposure to DEN, rats in the DEN cohort showed statistically equal values to the control cohort for all US parameters: echointensity, hepatorenal index (HRI), heterogeneity, and anisotropy (t-tests p = 0.62, 0.81, 0.24. 0.10, respectively; Fig. 1). Echointensity and hepatorenal index represent the echogenicity or brightness of the ultrasound images, with greater scattering and reflection of the ultrasound waves by the tissue leading to increased brightness. Echointensity is the mean brightness of the parenchyma analyzed in regions of interest (ROIs), and HRI normalizes that brightness to the right renal cortex intensity. As the DEN rats continued their diet, the liver echointensity increased (repeated measures ANOVA F2,39 = 59.6, p < 0.0005 for time points of 0, 10 and 13 weeks). Beginning at a baseline value of 37.1 ± SD 7.8, echointensity increased to 53.5 ± 5.7 at 10 weeks (p < 0.0005) and continued to increase to 57.7 ± 6.1 at 13 weeks (p < 0.0005, 0 to 13 weeks; p = 0.046, 10 to 13 weeks). In contrast, the control group showed no significant change in echointensity over time and showed a mean value of 34.6 ± 4.5 (F2,6 = 0.27, p = 0.77). Hepatorenal index rose from 0.28 ± 0.06 to 0.46 ± 0.10 at 10 weeks (p < 0.0005) and 0.53 ± 0.15 at 13 weeks in DEN rats (p < 0.0005, 0 to 13 weeks; p = 0.052 from 10 to 13 weeks; ANOVA F2,39 = 29.18, p < 0.0005). In the control rats, HRI remained an average of 0.25 ± 0.05 (F2,6 = 1.44, p = 0.31).
Similarly, in the DEN cohort the US measures of tissue variance increased over time (Fig. 1c,d). Heterogeneity is the standard deviation of brightness within ROIs and represents the local variance or speckle of the tissue. Anisotropy, used here to describe the variance in echogenicity between different spatial regions of the liver, is calculated as the standard deviation of brightness among ROIs in all planes imaged. Heterogeneity increased over time in the DEN-exposed rats but stayed constant at 225.7 ± 37.6 in control rats (F2,39 = 64.30, p < 0.0005 for DEN cohort; F2,6 = 0.57, p = 0.58 for controls). In the DEN cohort, heterogeneity rose from a baseline of 208.7 ± 58.3 to 344.6 ± 52.9 at 10 weeks and 376.8 ± 54.9 at 13 weeks (p < 0.0005, 0 to 10 weeks and 0 to 13 weeks; p = 0.06, 10 to 13 weeks). Anisotropy increased in a pattern similar to local heterogeneity. In control rats, anisotropy remained low over time at an average 8.96 ± 1.55 (F2,6 = 0.00, p = 0.9889). DEN-exposed rats’ anisotropy increased: baseline was 11.6 ± 3.0, statistically equal to the controls’ baseline (p = 0.10). Anisotropy in the DEN cohort then rose to 15.3 ± 3.4 at 10 weeks and 16.6 ± 2.2 at 13 weeks (ANOVA F2,39 = 29.18, p < 0.0005; 0 to 10 weeks, p < 0.0005 and 0 and 13 weeks, p = 0.18, 10 and 13 weeks).
Changes in brightness and variance of the liver parenchyma are shown in Fig. 2. The control rats remain dark with low speckle. The DEN cohort becomes brighter by the 10- and 13-week time points, demonstrating the increase in echointensity. The heterogeneity, which may be noted as speckle, is seen as grainier texture in the DEN cohort. For HRI, the brightness of the right renal cortex and liver parenchyma become more similar as fibrosis progresses and are nearly equal in F4. While visual effects are seen with echointensity, heterogeneity, and HRI, the anisotropy is difficult to appreciate visually because it measures fluctuation in the gray levels from multiple regions and images throughout the liver.
The intra-observer analysis showed no significant difference in echointensity, heterogeneity, or HRI at 0, 10, or 13 weeks (p > 0.05 for each time point for each measure, paired Student’s t-test). Though there were some statistical differences in anisotropy between analyses, the same pattern of increase was present on both analyses. The values from both analyses and the p-values for the intraobserver analysis are shown as Supplemental Information (SI Table 1).
Portal vein and inferior vena cava diameters remained constant over time, while the right hepatic vein diameter increased
The portal vein diameter was 1.71 mm ± 0.26 in controls and 1.70 mm ± 0.28 mm in the DEN cohort (p = 0.68) and did not change over time in control or DEN cohorts (F2,6 = 2.79, p = 0.16; F2,39 = 1.87, p = 0.18, respectively). Similarly, the IVC diameter stayed constant over time at an average of 4.07 mm ± 1.44. However, while the right hepatic vein stayed constant at 1.17 mm ± 0.37 in the control cohort (F2,6 = 0.33, p = 0.70), it increased over time in the DEN cohort (F2,24 = 6.17, p = 0.008). Right hepatic vein diameter rose from a baseline of 1.16 mm ± 0.33 to 1.30 mm ± 0.28 at 10 weeks and 1.62 ± 0.44 mm at 13 weeks (p = 0.002, 0 to 13 weeks; p = 0.02, 10 to 13 weeks). There was a trend toward significant difference between the DEN and control right hepatic veins at 13 weeks (p = 0.066).
Histopathologic analysis showed a spectrum of METAVIR grades of fibrosis between DEN and control cohorts
Scoring of multiple samples of each rat’s liver by a veterinary pathologist showed two control rats with a highest grade of F0 in any section. The other two control rats showed F1 as the highest grade present. Of note, control sections with F1 as opposed to F0 were accompanied by an acute inflammation and multifocal necrotizing hepatitis more consistent with an infection than the chronic inflammation, fibrosis, and nodular regeneration seen in DEN-exposed rats. The DEN rats all showed fibrosis with a METAVIR grade of F2 to F4. This spectrum of fibrotic changes is demonstrated in Fig. 2. The width of fiber bundles measured on trichrome-stained images of F2-F4 rats ranged from 7.60–80.21 micrometers, with a median of 18.83 micrometers.
Gross pathology of DEN-exposed animals showed varying nodularity and counts of lesions typically appearing white and solid with variable levels of hemorrhage and liquefaction. Cellular and architectural changes included multifocal to extensive hepatocellular hemorrhagic necrosis, lymphoplasmacytic infiltrate with few neutrophils, and portal and septal fibrosis with and without formation of nodules. Additionally, the livers showed multiple foci of karyomegaly, vacuolated cytoplasm, and lesions of hepatocellular carcinoma with foci of necrosis and hemorrhage. Neither DEN-exposed nor control rats showed notable steatosis.
Scoring of fibrosis using the METAVIR scale correlates with numeric values of US analysis and separates rats into distinct populations
Severe grades of fibrosis by METAVIR criteria corresponded with high sonographic measures of fibrosis. This relationship is demonstrated by nonparametric Spearman regressions showing increasing ultrasound values with increasing METAVIR grade (Fig. 3). The highest echointensity level observed (67.1) corresponded to a METAVIR grade of F4 (cirrhosis) while the lowest echointensity level (54.3) in the DEN cohort showed less fibrotic change and corresponded to a METAVIR grade of F2. The Spearman rho correlation coefficients for echointensity, HRI, heterogeneity, and anisotropy were 0.48, 0.53, 0.42, and 0.58, respectively. All correlations were significant (p < 0.04).
Additionally, the four features were used in combination to characterize the varying severities of fibrosis. An ordinal multiparametric logistic regression using all parameters was conducted, and stepwise backward selection included echointensity, heterogeneity, and anisotropy. HRI was excluded by this selection, most likely due to redundancy stemming from its relation to echointensity. The model was significant with a chi-squared = 23.75 significant at p < 0.00005. The model found a cut-point for prediction between F1 and F2 to have an odds ratio of 11.52 (standard error 3.79). When echointensity, heterogeneity, and anisotropy were plotted for each rat, the subjects separated into two distinct populations corresponding to the cutpoint between F1 and F2 (Fig. 4). The first population included rats with no or mild fibrosis (F0, F1), and the second population included rats with clinically significant fibrosis (≥F2).
The F0/F1 rats’ sonographic parameters at 13 weeks were found to agree with the DEN cohort’s baseline healthy tissue (p > 0.05, Supplemental Information Table 2), thereby suggesting that the control group is representative of clinically insignificant fibrosis demonstrated by a larger sample of healthy tissue. Additionally, the mean values and standard deviations of each feature for the DEN and Control groups were used to verify the sample size for the F0-F1 and F2-F4 groups (alpha = 0.05, power = 0.80). Anisotropy required the largest sample size (14 DEN rats +3 control rats), with other features requiring smaller sample sizes. Thus, the sample size selection of 22 DEN rats +4 control rats is appropriately powered to distinguish the clinically insignificant fibrosis and clinically significant fibrosis groups.
Cirrhosis is an increasing cause of death worldwide and in the United States. In addition to the traditional demographic of 45–55-year-olds, recent analyses show a 10.5% annual increase in mortality in 25–34-year-olds in the US2. This demonstrates the growing impact of cirrhosis on many populations with notable implications for public health. Preventing the development of cirrhosis and its complications, such as peritonitis, sepsis, variceal bleeding, ascites, and hepatic encephalopathy, will improve the outcomes of patients with chronic liver disease. Advancement in current methods of assessing and monitoring changes hepatic fibrosis will be important for patient management as well as for studies developing antifibrotic drugs24.
A noninvasive, broadly sampling, and quantitative assessment of hepatic fibrosis would reduce the need for hepatic biopsy with the attendant problems of procedural complications, sampling error, and subjectivity of a qualitative assessment of pathology. Previous reports of using ultrasound to detect cirrhosis showed inadequacy as detection relied on morphologic features accompanying end-stage cirrhosis, such as liver and spleen length, liver surface nodularity, hepatic vein straightness, and hepatic vein wall echogenicity12,15. Additionally, qualitative assessments of hepatic fibrosis have been used to characterize the echotexture as being fine, mildly coarse, coarse, and highly coarse17. In previous qualitative assessments of hepatic steatosis, operator dependency and subjectivity led to high inter- and intra-observer variability25. The accuracy of such evaluations may be improved through quantitative assessments of the images.
In this study, quantitative ultrasound features changed with verifiable progression of rats’ chronic liver disease and hepatic fibrogenesis. Specifically, DEN uniformly led to reduction in the weight gain of DEN-exposed rats, consistent with previous observations of this model26 and created progressive hepatic fibrosis verified by histologic evaluation. The four computer-extracted features studied in the B-mode US images (echointensity, HRI, heterogeneity, and anisotropy) consistently increased over time as hepatic disease progressed. Echointensity, or mean brightness of the liver parenchyma, increased significantly by the 10-week timepoint. Initial low levels of echointensity and speckle noise in the control and baseline scans are likely due to the homogenous nature of the tissue which lacks significant collagen and strong ultrasound scatterers. As fibrosis develops, collagen and an inflammatory cell infiltrate appear and could both act as acoustic scatterers to cause ultrasound wave backscatter and increase speckle brightness17. While brightness has been studied as a feature of steatosis, histologic assessment validated that the changes in US echointensity seen here occurred in a steatosis-free progression of fibrosis. The increase in mean brightness was also detected when normalizing the hepatic echointensity to that of the right renal cortex, or the hepatorenal index (HRI)13. HRI improved radiologic-pathologic correlation with the METAVIR grade of fibrosis (ρ = 0.48 in echointensity to 0.53 in HRI). This normalization technique may be used to minimize variation in instrumentation settings between a subject’s examinations and give the technique greater utility in retrospective clinical studies and in clinical practice20.
The two measures of variance studied, heterogeneity (local variations in echogenicity found within ROIs) and anisotropy (regional variations in echogenicity found between ROIs), also increased over time. These increases likely correspond to generalized formation of collagen septae and align with previous qualitative descriptions of an increased coarse texture in fibrotic livers27. In the fibrotic liver, the acoustic interfaces increase and the acoustic impedance difference between fibrotic tissue and hepatocytes becomes larger28. This leads to the observed coarse, echogenic pattern, with variation between areas with frequent collagen septae that scatter US and areas lacking septae. Regional differences demonstrated by increasing anisotropy may indicate variable severity of disease throughout the liver lobes. This is possibly related to variable distribution of portal blood flow and variable toxin distribution and metabolism. Furthermore, this calls attention to the fact that mixed levels of disease coexist. Understanding the most severe level of a patient’s disease as well as the amount of healthy liver reserve based on imaging could be helpful clinically. Aside from parenchymal markers, the increasing right hepatic vein diameter may be due to liver tissue contraction causing venous expansion rather than elevated luminal hepatic venous pressure, and serve as an easily quantifiable marker of progressing chronic liver disease. These imaging biomarkers may serve as an early exploration into the use of quantitative ultrasound biomarkers and radiomics in ultrasound.
This set of imaging biomarkers may also provide a platform for the development of artificial intelligence and radiomics in clinical ultrasound, by relating biomarkers from imaging datasets with pathologic METAVIR staging. Beyond looking at each sonographic feature on its own, we grouped measures of brightness and variation together to characterize the stages of fibrosis. When analyzing echointensity, heterogeneity, and anisotropy simultaneously, two distinct populations of METAVIR grades were distinguished. The first included F0-F1 (no fibrosis to portal fibrosis), which is considered clinically insignificant and does not warrant treatment in the case of viral disease. The second population represents “clinically significant fibrosis” comprising F2-F4: minimal septae, numerous septae, and bridging fibrosis (cirrhosis). Clinically, these patients require more active management. Within these groups there is some overlap between METAVIR categories, which may reflect the temporal and spatial heterogeneity of fibrosis between lobes29,30. However, the distinction between clinically significant and clinically insignificant disease using these three imaging biomarkers indicates that both brightness and variance measures are useful in characterizing the development of fibrosis using ultrasound. The implementation of a multiple-biomarker approach using these quantitative features in isolation or in combination with additional imaging features, serum biomarkers, and clinical information may ultimately provide the optimal predictor of clinical outcome.
In this study, imaging was performed at frequencies greater than those used for clinical scanning (21 MHz versus 3–7 MHz). Details of the tissue microstructure in the echosignal depend on the ultrasound frequency of the imaging pulse31,32,33,34. Higher frequency provides higher spatial resolution35 and greater backscatter36,37,38. The use of a higher frequency potentially provides more detailed information on tissue microstructure than is possible with current clinical imaging systems. This benefit, however, comes at the expense of shallower penetration due to greater attenuation of ultrasound.
In addition to frequency, the tissue microstructure, including the tissue composition, fiber size, cell density, and cell size, also affect the ultrasound backscatter34. The architecture of the liver is complex and consists of hepatocytes organized into larger units called acini, which develop a significant component of collagen fibers during fibrosis39. In humans compared to rats, hepatocytes are roughly equivalent in size40,41,42, acini are twice as large39,43, and the maximum fiber thicknesses44 are twice of those reported in this study (Table 2 Supplemental Information). These differences in microstructure between the two species could influence the echogenicity. On one hand, the lower frequency used in clinical scanning would result in lower scatter, but on the other hand, the larger scale of the tissue microstructure in humans would create greater scatter. These opposing effects likely have a complex interplay on the net echogenicity, which is not well understood for complex media such as the liver microstructure’s multiple scales of acoustic scatterers (cells, fibers, fiber-encircled acini and nodules). The larger scale of human tissue components may explain the ability of clinical gray scale ultrasound to observe textural and echogenic changes previously12,16,27,28. Further validation by side-by-side comparison of high and low frequency ultrasound in human subjects would provide better insight into whether the studied tissue changes are apparent using clinical scanners.
The benefits of B-mode US include the widespread availability of imaging systems, its capability to assess hepatic parenchyma concurrently with ascites, hepatic masses, or other abdominal indications, and its ability to image a large liver volume to reduce sampling error. By further standardizing and automating ROI selection, measurement could occur automatically in clinical abdominal ultrasound examinations to assess liver health. This easily accessible, noninvasive tool could improve longitudinal monitoring of disease progression or response to therapy while avoiding the need for multiple biopsies.
Limitations of our study include the possible changes in fibrosis between 13-week imaging and sacrifice and the use of a controlled model of fibrosis, which may not account for concurrent liver pathology from varying etiologies. Previous studies on nitrosamine-induced fibrosis show mix of fibrosis progression, regression, and stability after stoppage of toxin administration. While some evidence shows a reduction in the collagen after stopping the toxin45, other studies showed progression in fibrosis between 2–24 weeks after stoppage46. This progression was hypothesized to be due to genotoxic or metabolic insults to hepatocytes during toxin administration. Variation due to either of these processes could affect the correlation between US imaging and METAVIR staging in this study, potentially causing some of the variability observed. Regarding specificity of US findings to fibrosis versus other liver pathology13, results indicated absence of steatosis. This indicates the sonographic changes observed here were not part of steatosis but were due to fibrosis. While echogenicity does increase with steatosis, the accompanying changes in heterogeneity and anisotropy may help identify fibrosis more specifically. Our data was collected under controlled imaging conditions including a fixed time-gain-compensation. Normalization via measures such as HRI may account for changing imaging parameters. The HRI may also help assess longitudinal changes despite ultrasound gain settings varying between studies.
In conclusion, we found that computer-extracted features of B-mode US images consistently increased over time in a quantifiable manner as hepatic damage and fibrosis progressed. In clinical practice, these unbiased quantitative US measures could inexpensively and quickly provide a quantitative measurement of the extent of hepatic fibrosis. In the future, these techniques may be applied to strengthen the clinical diagnosis and assessment of hepatic fibrosis and chronic liver disease. Going forward, these findings need to be validated in human subjects. Specifically, it should be confirmed whether the features measured at high frequency in this study can also be reliably measured and utilized at clinical frequencies.
All animal studies and protocols were approved by the University’s Institutional Animal Care and Use Committee. All methods were performed in accordance with the relevant guidelines and regulations. Twenty-two male Wistar rats (procured at 350–400 g body weight from Charles River Laboratories) were acclimated in the housing facilities for one week. They then began a diet of 0.01% diethylnitrosamine (DEN) (Sigma Aldrich, St. Louis, MO, USA) in their drinking water, ingested ad libitum for 12 weeks. The DEN model has been well-developed as a model of fibrosis and hepatocellular carcinoma47,48. The changes and spectrum of disease in fibrogenesis have also been utilized in imaging studies to track the progression of fibrosis49. As a control group, four rats were not fed DEN in their drinking water. The rats were euthanized using carbon dioxide asphyxiation or died naturally after tumors had developed, 108–135 days from the start of the DEN or control diet. A necropsy was performed and tissue from lobes in the right and left sides of the liver was harvested for histologic examination.
Image acquisition and analysis
Sonographic images (Visualsonics VevoLAZR, Fujifilm, Toronto, Canada) of each rat were acquired at three time points: before diet initiation (0 weeks) and 10 and 13 weeks after the start of DEN administration (Fig. 5). Four to six B-mode images were acquired in standard transverse and sagittal imaging planes of the right and left lobes of the liver and the right liver-kidney interface. Imaging presets (gain = 18 dB, high sensitivity, 100% power, transmit frequency 21 MHz, and high line density) and time compensation gain were optimized and standardized. Four to eight regions of interest (ROI) were selected manually by a trained radiologist (LRS) to ensure comprehensive inclusion of multiple representative parts of the liver parenchyma and exclusion of imaging artifacts such as acoustic shadowing, enhancement, or reverberation. Intraobserver analysis was conducted on the same images with new ROI placement after more than one month, ensuring lack of memory bias. ROIs were analyzed offline using MaZda software (V 4.6, Technical University of Lodz: Lodz, Poland) for echointensity (brightness level), heterogeneity (local variance within ROIs), anisotropy (regional variance between ROIs), and hepatorenal index (HRI; brightness normalized to renal cortex)50. The ROI values for each parameter were averaged for each rat.
The features extracted from each ROI are statistical computations that represent the real texture of the tissue. The tissue’s nondeterministic properties govern the distributions and relationships between the gray levels of an image, which are then analyzed by the Mazda software. Echointensity and heterogeneity features are computed directly from the intensity of the pixels, taken from the mean intensity and standard deviation of intensity. Anisotropy is the calculated standard deviation of the echointensity between the ROIs in all the planes measured throughout the liver. Hepatorenal index is calculated from the mean of three ROIs placed in the hepatic tissue adjacent to the right kidney divided by the mean of three ROI placed in the renal cortex.
Vascular measurements were measured from B-mode images obtained at baseline, 10 weeks and 13 weeks. Diameters of the right hepatic vein, inferior vena cava and portal vein were measured using Vevolab software (Visualsonics, Fujifilm, Toronto, Canada).
At necropsy, the liver lobes were assessed for fibrosis and nodularity on gross pathology. Portions of non-tumorous liver were preserved in 10% phosphate-buffered formalin and transferred to 50% ethanol after 48–72 hours and then embedded in paraffin and processed for histological examination with hematoxylin and eosin (H&E) and trichrome staining. Each histologic section was graded according to METAVIR scoring system. For animals in which multiple grades of fibrosis were identified, the highest-grade present was used to characterize the severity of fibrosis for that rat. Sonographic-pathologic correlations were made by correlating the imaging features at final the time point (13 weeks) with the METAVIR score.
Imaging features (echointensity, HRI, heterogeneity, anisotropy, and vascular measurements) in the DEN and control groups were assessed for a significant change over the three time points using a repeated measures ANOVA. The Greenhouse-Geisser correction for sphericity was used. Subsequent pairwise two-tailed Student’s t-tests using the least significant difference method were used between timepoints for ANOVA tests showing a significant difference. A two-tailed t-test was also performed to look for differences between the treated and control groups at each time point. Paired Student’s t-tests between the initial and repeated values of tissue features were used for intraobserver analysis. Spearman correlations were made between the non-parametric semi-quantitative, ordinal data of the METAVIR scoring system and the numeric values of the sonographic analyses. An ordinal multiparametric logistic regression was carried out with all four features and the METAVIR score. A stepwise backward selection with 0.2 significance for removal and 0.1 significance for addition was used to select which features best correlated with the histologic score. An alpha of 0.05 was considered statistically significant. Statistics were calculated using Stata version 15.0, StataCorp, College Station, TX51.
Scaglione, S. et al. The epidemiology of cirrhosis in the United States a population-based study. J. Clin. Gastroenterol. 49, 690–696 (2015).
Tapper, E. B. & Parikh, N. D. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 362, k2817 (2018).
Haga, Y. et al. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J. Gastroenterol. 21, 12989–95 (2015).
Lim, Y.-S. & Kim, W. R. The Global Impact of Hepatic Fibrosis and End-Stage Liver Disease. Clin. Liver Dis. 12, 733–746 (2008).
Wanless, I. R. Pathogenesis of cirrhosis. J. Gastroenterol. Hepatol. 19, S369–S371 (2004).
Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 24, 289–293 (1996).
Bedossa, P., Dargere, D. & Paradis, V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38, ajhep09022 (2003).
Denzer, U. W. & Lüth, S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract. Res. Clin. Gastroenterol. 23, 453–460 (2009).
Frulio, N. & Trillaud, H. Ultrasound elastography in liver. Diagn. Interv. Imaging 94, 515–534 (2013).
Friedrich–Rust, M. et al. Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis. Gastroenterology 134, 960–974.e8 (2008).
Friedrich-Rust, M. et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: A pooled meta-analysis. J. Viral Hepat, https://doi.org/10.1111/j.1365-2893.2011.01537.x (2012).
Aubé, C. et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J. Hepatol. 30, 472–8 (1999).
Chauhan, A. et al. Diagnostic accuracy of hepatorenal index in the detection and grading of hepatic steatosis. J. Clin. Ultrasound 44, 580–586 (2016).
Cengiz, M., Sentürk, S., Cetin, B., Bayrak, A. H. & Bilek, S. U. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int. J. Clin. Exp. Med. 7, 5453–60 (2014).
Strauss, S., Gavish, E., Gottlieb, P. & Katsnelson, L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR. Am. J. Roentgenol. 189, W320–3 (2007).
Nishiura, T. et al. Ultrasound evaluation of the fibrosis stage in chronic liver disease by the simultaneous use of low and high frequency probes. Br. J. Radiol. 78, 189–197 (2005).
Gerstenmaier, J. F. & Gibson, R. N. Ultrasound in chronic liver disease. Insights Imaging 5, 441–55 (2014).
Joseph, A. E., Saverymuttu, S. H., al-Sam, S., Cook, M. G. & Maxwell, J. D. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin. Radiol. 43, 26–31 (1991).
Rix, A. et al. Advanced Ultrasound Technologies for Diagnosis and Therapy. J. Nucl. Med. 59, 740–746 (2018).
Webb, M. et al. Diagnostic Value of a Computerized Hepatorenal Index for Sonographic Quantification of Liver Steatosis. Am. J. Roentgenol. 192, 909–914 (2009).
Lessa, A. S. et al. Ultrasound imaging in an experimental model of fatty liver disease and cirrhosis in rats. BMC Vet. Res. 6, 6 (2010).
de Lima, V. M. R. et al. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma. J. Hepatol. 49, 1055–1061 (2008).
Liao, A.-H. et al. Characterization of Malignant Focal Liver Lesions with Contrast-Enhanced 40 MHz Ultrasound Imaging in Hepatitis B Virus X Transgenic Mice: A Feasibility Study. Ultrason. Imaging 30, 203–216 (2008).
Cohen-Naftaly, M. & Friedman, S. L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap. Adv. Gastroenterol. 4, 391–417 (2011).
Schwenzer, N. F. et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. https://doi.org/10.1016/j.jhep.2009.05.023 (2009).
Kiefer, R. M. et al. Relative Initial Weight Is Associated with Improved Survival without Altering Tumor Latency in a Translational Rat Model of Diethylnitrosamine-Induced Hepatocellular Carcinoma and Transarterial Embolization. J. Vasc. Interv. Radiol. 28, 1043–1050.e2 (2017).
Saverymuttu, S. H., Joseph, A. E. A. & Maxwell, J. D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br. Med. J. (Clin. Res. Ed), https://doi.org/10.1136/bmj.292.6512.13 (1986).
Zheng, R.-Q. et al. Liver fibrosis in chronic viral hepatitis: an ultrasonographic study. World J. Gastroenterol. 9, 2484–9 (2003).
Gascon-Barre, M., Huet, P. M., Belgiorno, J., Plourde, V. & Coulombe, P. A. Estimation of collagen content of liver specimens. Variation among animals and among hepatic lobes in cirrhotic rats. J. Histochem. Cytochem, https://doi.org/10.1177/37.3.2465335 (1989).
Soloway, R. D., Baggenstoss, A. H., Schoenfield, L. J. & Summerskill, W. H. J. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am. J. Dig. Dis, https://doi.org/10.1007/BF02235164 (1971).
Doyle, T. E., Warnick, K. H. & Carruth, B. L. Histology-based simulations for the ultrasonic detection of microscopic cancer in vivo. J. Acoust. Soc. Am. 122, EL210–EL216 (2007).
Oelze, M. L., Zachary, J. F. & O’Brien, W. D. Characterization of tissue microstructure using ultrasonic backscatter: Theory and technique for optimization using a Gaussian form factor. J. Acoust. Soc. Am. 112, 1202–1211 (2002).
Insana, M. F. Modeling acoustic backscatter from kidney microstructure using an anisotropic correlation function. J. Acoust. Soc. Am. 97, 649–655 (1995).
Daoud, M. I. & Lacefield, J. C. Stochastic Modeling of Normal and Tumor Tissue Microstructure for High-Frequency Ultrasound Imaging Simulations. IEEE Trans. Biomed. Eng. 56, 2806–2815 (2009).
Shung, K. K. High Frequency Ultrasonic Imaging. J. Med. Ultrasound 17, 25–30 (2009).
Nicholas, D. Evaluation of Backscattering Coefficients for Excised Human Tissues: Results, Interpretation and Associated Measurements. Ultrasound in Med. & Bi ol 8 (1982).
Sehgal, C. M. & Greenleaf, J. F. Scattering of ultrasound by tissues. Ultrason. Imaging 6, 60–80 (1984).
Liu, X.-Z., Gong, X.-F., Zhang, D., Ye, S.-G. & Rui, B. Ultrasonic characterization of porcine liver tissue at frequency between 25 to 55 MHz. World J. Gastroenterol. 12, 2276–9 (2006).
Rappaport, A. M. & Wilson, W. D. The stuctural and functional unit in the human liver (liver acinus). Anat. Rec. 130, 673–689 (1958).
Lodish, H. et al. Molecular Cell Biology (Fifth Edition). W. H. Freeman and Company. New York, pp 10 (2000).
Weibel, E. R., Stäubli, W., Gnägi, H. R. & Hess, F. A. Correlated morphometric and biochemical studies on the liver cell. I. Morphometric model, stereologic methods, and normal morphometric data for rat liver. J Cell Biol. 42(1), 68–91 (1969).
Engelmann, G. L., Richardson, A., Katz, A. & Fierer, J. A. Age-related changes in isolated rat hepatocytes. Comparison of size, morphology, binucleation, and protein content. Mech. Ageing Dev. 16, 385–395 (1981).
Teutsch, H. F. The modular microarchitecture of human liver. Hepatology 42, 317–325 (2005).
Wang, B. et al. Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients. Mod. Pathol. 31, 1567–1577 (2018).
Jézéquel, A. M. et al. A morphological study of the early stages of hepatic fibrosis induced by low doses of dimethylnitrosamine in the rat. J. Hepatol. 5, 174–181 (1987).
Jenkins, S. A. et al. A Dimethylnitrosamine-Induced Model of Cirrhosis and Portal Hypertension in the Rat. Journal of Hepatology 1 (1985).
Sta, P. & Leclercq, I. Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under. Development. J. Clin. Transl. Hepatol. 3, 53–66 (2015).
Liedtke, C. et al. Experimental liver fibrosis research: Update on animal models, legal issues and translational aspects. Fibrogenesis and Tissue Repair, https://doi.org/10.1186/1755-1536-6-19 (2013).
Jin, N. et al. Carbogen Gas–Challenge BOLD MR Imaging in a Rat Model of Diethylnitrosamine-induced Liver Fibrosis. Radiology, https://doi.org/10.1148/radiol.09090410 (2010).
Szczypiński, P. M., Strzelecki, M., Materka, A. & Klepaczko, A. MaZda—A software package for image texture analysis. Comput. Methods Programs Biomed. 94, 66–76 (2009).
StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC (2017).
The financial support from NIH grants CA204446-01, EB022612-01, and S10OD016310 is gratefully acknowledged. Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number TL1TR001880. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We appreciate the valuable contributions from Terence P. Gade MD, PhD and Ryan M. Kiefer MD in the animal studies and Sean Carlin, PhD in histology analysis. We also would like to thank Andrew J. Cucchiara, PhD for assistance in statistical analysis.
The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
D’Souza, J.C., Sultan, L.R., Hunt, S.J. et al. B-mode ultrasound for the assessment of hepatic fibrosis: a quantitative multiparametric analysis for a radiomics approach. Sci Rep 9, 8708 (2019). https://doi.org/10.1038/s41598-019-45043-z
Subsequent Ultrasound Vascular Targeting Therapy of Hepatocellular Carcinoma Improves the Treatment Efficacy
The Roles of Ultrasound-Based Radiomics In Precision Diagnosis and Treatment of Different Cancers: A Literature Review
ADVANCED ULTRASOUND IN DIAGNOSIS AND THERAPY (2020)
Ultrasound in Medicine & Biology (2020)
Frontiers in Oncology (2020)